CASZ1 and neoplasm: No tumor-associated nucleotide mutations have been reported in the CASZ1-coding sequence, suggesting that mechanisms such as epigenetic silencing may be associated with reduced CASZ1 expression in tumors from patients with poor prognosis [63, 64].